ÖzetAmaç: Büllöz hastalıklar; deri ve mukozaları tutan, doku adezyon moleküllerine karşı spesifik antikorlarla gelişen ya da genetik kalıtımın neden olduğu bir grup hastalıktır. Ülkemizde bu hastalıkları inceleyen detaylı epidemiyolojik çalışma sınırlıdır. Bu amaçla Orta Anadolu'da Konya yöresi ve civarında yaşayan büllöz hastalığı olan olguların demografik, klinik, immünopatolojik, tedavi ve takiplerindeki özellikleri sunmaktayız. Gereç ve Yöntem: Çalışmamızda 2006-2012 yılları arasında büllöz hastalık tanısıyla takip edilmiş olan 93 olgunun verileri retrospektif değerlendirildi. Olgularımızın çoğunluğu pemfigus ve büllöz pemfigoid grubunda olduğu için onlara ait veriler daha detaylı irdelendi. Bulgular: Çalışmaya dahil edilen 93 olgunun 50'si (%53,8) kadın, 43'ü (%46,2) erkekti. Yaş ortalaması 52,9 yıldı. Olgulardan %37,6'sı pemfigus vulgaris, %34,4'ü büllöz pemfigoid, %15'i herediter epidermolizis bülloza, %4,3'ü dermatitis herpetiformis, %4,3'ü pemfigus foliaseus, %2,2'i pemfigus vegetans, %1,1'i Hailey-Hailey hastalığı %1,1'i skatrisyel pemfigoid tanısı almıştı. Pemfigus vulgarisin ortaya çıkış yaş ortalaması 45,9 yıldı ve kadınlarda daha fazla görüldü. Pemfigus vulgarisli olgularda hastalık oral mukozadan başladı ve diğer coğrafik bölgelere göre; oral mukoza tutulumu ile başlayan pemfigus vulgarisli olgularda tanı alma süresi daha uzundu. Büllöz pemfigoidin ortaya çıkış yaş ortalaması 70 yıldı ve kadınlarda daha fazla görüldü. Olguların %12,5'inde hastalık oral mukozadan başladı. Hiçbir olguda eşlik eden otoimmün hastalık saptanmadı. Doksan üç olgunun 25'ine sadece sistemik steroid, 41'ine sistemik steroid ve adjuvan, 11'ine sadece adjuvan, 16'sına sadece lokal tedaviler verildi. Sum maryBackgroundandDesign:Bullous diseases are a group of disorders caused by specific antibodies against tissue adhesion molecules in the skin and mucosa or by genetic inheritance. There are limited detailed epidemiological studies about bullous disorders in Turkey. In this study, we evaluated the demographic, clinical and immunopathological findings as well as course of the disease and follow-up properties in patients with bullous disorders in the Province of Konya. MaterialsandMethods:Ninety-three patients, who were followed up between 2006 and 2012, were included in our study. Since most of the patients were in pemphigus and bullous pemphigoid groups, we investigated data on those patients in more detail. Results:53.8% of patients were female and 46.2% were male. The mean age was 52.9. 37.6% of patients had pemphigus vulgaris, -34.4% bullous pemphigoid, -15%hereditary epidermolysis bullosa, -4.3% dermatitis herpetiformis, -4.3% pemphigus foliaceus, -2.2% pemphigus vegetans, -1.1% Hailey-Hailey disease, and 1.1% of patients had cicatricial pemphigoid. The mean age of onset of pemhigus vulgaris was 45.9
Cutaneous side effects during anti TNF therapies can be classified by their clinical and histopathologic features. Infusion and injection side reactions, vasculitis, psoriasis and psoriasiform eruption, drug-induced lupus, cutaneous infections, eczematous and lichenoid reactions, granulomatous diseases, cutaneous lymphoma, morphea, non-melanoma skin carcinomas, and melanoma are the dermatologic side effects that can be seen during anti TNF therapies. In this case report, we aimed to emphasize the cutaneous side effects during anti TNF agent therapies. Pustular bacterid of Andrews has never been reported as a side effect during anti TNF therapies. In fact, it can be classified as a local form of pustular psoriasis. Here, we report a case of pustular bacterid of Andrews as a psoriasiform side effect seen during infliximab therapy.
Background and Design: Dermoscopy is a rapid and reliable method in the diagnosis of pigmented skin lesions, but dermoscopic examination of palmoplantar region is different due to the anatomical structures of acral region. The number of studies on the dermoscopy of acral melanocytic lesions is limited and acral volar melanocytic lesions were examined in all studies. For this reason, we aimed to examine acral melanocytic nevi located on the volar and dorsal side, to investigate the clinical and dermoscopic features, and to report the first demographic study of acral melanocytic nevi in the Central Anatolian Region of Turkey. Materials and Methods: The study included a total of 97 patients with 143 lesions, who were admitted to
Lipoid proteinosis, which is known as "Urbach-Wiethe disease", was first described in 1929 as "lipoidosis cutis et mucosae" by Urbach and Wiethe. It is a rare autosomal recessive inherited genodermatosis. There are PAS-positive hyaline material deposits in the skin, mucosa and visceral organs. A 23-year-old man, who was suffering from swelling of the lower lip and a fissure on the inner side of the lip, presented to our outpatient clinic. On dermatological examination, there were lower lip edema and infiltration, as well as macroglossia. There were bilateral yellowish papules along his eyelashes. For his ocular findings; it was learned that he had been treated for trichiasis at his childhood. There were multiple atrophic scars on his face, elbows, axilla, knees, and the skin overlying his spinous processes. He had no hoarseness. There was no consanguinity between his mother and father. Physical examination was normal. Three punch biopsies were carried out from his tongue, lips and elbow with the preliminary diagnoses of lipoid proteinosis, Melkersson-Rosenthal syndrome, focal epithelial hyperplasia, amyloidosis, granulomatous cheilitis, atrofoderma, and anetoderma. Deposition of hyaline PAS-positive materials was observed on his histopathological examination. According to the clinical and histopathological findings, the patient was diagnosed as having lipoid proteinosis. Otorhinolaryngologists, ophthalmologists, dermatologists, and neurologists should keep this rare condition in mind in the differential diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.